VA Class: DE102
Chemical Name: (2E)-2-[(4R)-4-(2,4-Dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-imidazol-1-ylacetonitrile
Molecular Formula: C14H9Cl2N3S2
CAS Number: 187164-19-8
Antifungal; azole (imidazole derivative).
Uses for Luliconazole
Treatment of tinea corporis (body ringworm) and tinea cruris (jock itch, groin ringworm) caused by Epidermophyton floccosum or Trichophyton rubrum.
Treatment of interdigital tinea pedis (athlete’s foot, foot ringworm) caused by E. floccosum or T. rubrum.
Topical antifungals usually effective for treatment of tinea corporis and tinea cruris. An oral antifungal may be necessary if tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, the infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy.
Topical antifungals usually effective for treatment of uncomplicated tinea pedis. An oral antifungal usually necessary if tinea pedis is extensive, the infection is chronic or does not respond to topical therapy, patient is immunocompromised because of coexisting disease or concomitant therapy, or the infection involves hyperkeratotic areas on palms and soles or chronic moccasin-type (dry-type) tinea pedis.
Luliconazole Dosage and Administration
Apply topically to skin as a 1% cream.
Do not administer orally or intravaginally; do not apply topically to eyes.
Apply sufficient amount of cream to cover affected areas and approximately 1 inch of surrounding healthy skin.
Wash hands after applying the cream.
Tinea Corporis or Tinea CrurisTopical
Apply 1% cream once daily for 1 week. Use amount sufficient to cover affected area and approximately 1 inch of surrounding healthy skin.
Tinea Pedis (Interdigital)Topical
Apply 1% cream once daily for 2 weeks. Use amount sufficient to cover affected area and approximately 1 inch of surrounding healthy skin.
No special population dosage recommendations.
Cautions for Luliconazole
Manufacturer states none.
Contact dermatitis reported following topical application of 1% cream. Cross-sensitivity to both luliconazole and lanoconazole (not commercially available in US) reported.
Local irritation may occur.
For topical use only. Do not use orally or intravaginally; do not apply to eyes.
Selection and Use of Antifungals
Prior to initiation of treatment of dermatophytoses, confirm diagnosis by direct microscopic examination of scrapings from infected tissue mounted in potassium hydroxide (KOH) or by culture.
Not known whether distributed into milk following topical application of 1% cream. Use with caution in nursing women.
Safety and efficacy not established in children.
No substantial differences in safety and efficacy relative to younger adults, but increased sensitivity cannot be ruled out.
Common Adverse Effects
Application site reactions, including pruritus and pain.
Interactions for Luliconazole
May inhibit CYP2C19 and 3A4; clinically important interactions with CYP2C19 and 3A4 substrates unlikely because systemic exposure is low following topical application of luliconazole to skin. Inhibition of CYP1A2, 2C9, and 2D6 not expected.
No formal drug interaction studies to date.
Following topical application of luliconazole 1% cream to skin, low concentrations are absorbed systemically.
Adults with moderate to severe tinea cruris: Once-daily application of 1% cream to affected and surrounding areas of skin (approximately 3.5 g daily) for 15 days resulted in mean peak plasma concentrations of 4.91 ng/mL after first dose and 7.36 ng/mL after final dose; time to peak concentrations was 21 and 6.5 hours, respectively.
Adults with moderate to severe tinea pedis: Once-daily application of 1% cream to affected and surrounding areas of skin (approximately 3.5 g daily) for 15 days resulted in mean peak plasma concentrations of 0.4 ng/mL after first dose and 0.93 ng/mL after final dose; time to peak concentrations was 16.9 and 5.8 hours, respectively.
Not known whether distributed into milk following topical application of 1% cream.
Plasma Protein Binding
In vitro studies suggest systemically absorbed luliconazole may be metabolized by CYP2D6 and 3A4.
Mean plasma half-life was 21.1 or 32.4 hours on day 15 of once-daily topical application of 1% cream in adults with tinea cruris or tinea pedis, respectively.
20–25°C (may be exposed to 15–30°C).
Actions and Spectrum
Imidazole-derivative azole antifungal.
Exact mechanism of action not fully determined. Antifungal activity appears to result from interference with ergosterol synthesis via inhibition of C-14 demethylation of sterol intermediates (e.g., lanosterol). This results in decreased amounts of ergosterol, a constituent of fungal cell membranes, and accumulation of lanosterol.
Spectrum of activity includes dermatophytes, yeasts, and some other fungi.
Dermatophytes: Active in vitro against Epidermophyton floccosum, Trichophyton mentagrophytes, T. rubrum, T. tonsurans, T. verrucosum, T. violaceum, Microsporum canis, and M. gypseum.
Other fungi: Active in vitro against Candida albicans, Malassezia furfur, M. restricta, M. slooffiae, and M. sympodialis.
Some evidence that luliconazole may be more active than terbinafine against dermatophytes and C. albicans in vitro.
Advice to Patients
Importance of using luliconazole cream only for the condition prescribed.
Advise patients that the cream is for external use only and to avoid contact with eyes, mouth, or vagina.
Advise patients to wash their hands after applying the cream to affected areas.
Advise patients that skin irritation may occur; importance of reporting any application site adverse reactions.
Importance of informing clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses.
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.
Importance of informing patients of other important precautionary information. (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
AHFS DI Essentials™. © Copyright 2021, Selected Revisions February 12, 2015. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
More about luliconazole topical
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Pricing & Coupons
- En Español
- Drug class: topical antifungals